SEC CIK 1204632
HENSLEY ROBIN
Reported ownership across 1 company, sourced from SEC Form 4 filings and updated daily.
Current Positions
| Company | Shares Owned | As Of |
|---|---|---|
| SGCview stock → | 50,293 | 2023-11-08 |
Position History — SGC
Reported shares owned immediately after each Form 4 transaction, over time.
Recent Filings — SGC
| Date | Activity | Shares | Price | Owned After |
|---|---|---|---|---|
| 2023-11-08 | Grant / award | 7,537 | — | 50,293 |
| 2023-05-12 | Grant / award (derivative) | 2,750 | $8.33 | 2,750 |
| 2022-11-04 | Grant / award | 6,909 | — | 42,756 |
| 2022-05-13 | Grant / award (derivative) | 2,750 | $16.18 | 2,750 |
| 2021-11-11 | Grant / award | 2,733 | — | 35,847 |
| 2021-05-14 | Grant / award (derivative) | 2,750 | $26.13 | 2,750 |
| 2020-11-06 | Grant / award | 3,364 | — | 33,114 |
| 2020-08-25 | Option exercise (derivative) | 4,000 | $0.00 | 0 |
| 2020-08-25 | Open-market sale | 25,000 | $22.78 | 29,750 |
| 2020-08-25 | Option exercise | 7,000 | $7.96 | 54,750 |
| 2020-08-25 | Option exercise | 7,000 | $5.85 | 47,750 |
| 2020-08-25 | Option exercise | 7,000 | $5.88 | 40,750 |
| 2020-08-25 | Option exercise | 4,000 | $5.55 | 33,750 |
| 2020-08-24 | Option exercise (derivative) | 3,000 | $0.00 | 0 |
| 2020-08-24 | Option exercise | 3,000 | $5.55 | 32,750 |
| 2020-08-24 | Open-market sale | 3,000 | $23.61 | 29,750 |
| 2020-05-12 | Grant / award (derivative) | 2,750 | $8.48 | 2,750 |
| 2020-05-12 | Grant / award (derivative) | 3,028 | $8.48 | 3,028 |
| 2020-04-29 | Option exercise (derivative) | 7,000 | $0.00 | 0 |
| 2020-04-29 | Option exercise | 7,000 | $4.71 | 37,930 |
| 2020-04-29 | Tax withholding | 4,380 | $7.52 | 33,550 |
| 2019-11-12 | Open-market sale | 950 | $14.78 | 30,930 |
| 2019-11-01 | Grant / award | 3,943 | — | 31,880 |
| 2019-05-20 | Open-market sale | 1,907 | $16.50 | 27,937 |
| 2019-05-03 | Grant / award (derivative) | 2,750 | $16.84 | 2,750 |
| 2019-04-26 | Option exercise (derivative) | 6,000 | $0.00 | 0 |
| 2019-04-26 | Option exercise | 6,000 | $3.82 | 31,111 |
| 2019-04-26 | Tax withholding | 1,267 | $18.07 | 29,844 |
| 2018-11-15 | Open-market sale | 2,829 | $18.85 | 25,111 |
| 2018-11-02 | Grant / award | 3,064 | — | 27,940 |
| 2018-05-03 | Grant / award (derivative) | 2,750 | $24.28 | 2,750 |
| 2018-04-19 | Option exercise (derivative) | 6,000 | $0.00 | 0 |
| 2018-04-19 | Tax withholding | 1,031 | $26.83 | 24,876 |
| 2018-04-19 | Option exercise | 6,000 | $4.61 | 25,907 |
| 2017-11-01 | Grant / award | 2,138 | — | 19,907 |
| 2017-05-05 | Grant / award (derivative) | 2,750 | $18.05 | 2,750 |
| 2017-05-02 | Option exercise (derivative) | 5,000 | $0.00 | 0 |
| 2017-05-02 | Option exercise | 5,000 | $6.18 | 17,769 |
| 2016-11-04 | Grant / award | 2,446 | $16.35 | 12,769 |
| 2016-05-06 | Grant / award (derivative) | 2,750 | $18.55 | 2,750 |
| 2016-04-20 | Option exercise (derivative) | 5,000 | $6.42 | 0 |
| 2016-04-20 | Option exercise | 5,000 | $6.42 | 10,323 |
| 2015-11-06 | Grant / award | 1,819 | $17.59 | 5,323 |
| 2015-05-05 | Open-market sale | 3,330 | $16.50 | 3,504 |
| 2015-05-01 | Grant / award (derivative) | 2,750 | $16.78 | 2,750 |
| 2015-04-28 | Option exercise (derivative) | 5,000 | $0.00 | 0 |
| 2015-04-28 | Option exercise | 5,000 | $5.78 | 8,504 |
| 2015-04-28 | Open-market sale | 1,670 | $18.30 | 6,834 |
| 2014-11-07 | Grant / award | 752 | — | 1,752 |
| 2014-05-02 | Grant / award (derivative) | 3,500 | $15.91 | 3,500 |
| 2013-05-02 | Grant / award (derivative) | 3,500 | $11.70 | 3,500 |
| 2012-05-04 | Grant / award (derivative) | 3,500 | $11.75 | 3,500 |
| 2011-05-06 | Grant / award (derivative) | 3,500 | $11.10 | 3,500 |
| 2010-05-04 | Grant / award (derivative) | 3,500 | $9.41 | 3,500 |
| 2009-05-01 | Grant / award (derivative) | 3,000 | $7.63 | 3,000 |
| 2008-05-02 | Grant / award (derivative) | 3,000 | $9.22 | 3,000 |
| 2007-08-03 | Grant / award (derivative) | 2,500 | $12.35 | 2,500 |
| 2006-05-05 | Grant / award (derivative) | 2,500 | $12.84 | 2,500 |
Source: SEC EDGAR Form 4 filings. For informational purposes only — not investment advice.